The stock of Hims & Hers Health Inc (NYSE:HIMS) last traded at $48.42, up 0.92% from the previous session.
HIMS stock price is now -5.08% away from the 50-day moving average and 38.76% away from the 200-day moving average. The market capitalization of the company currently stands at $10.84B.
On June 04, 2025, Needham reiterated its ‘Buy’ rating on the stock by increasing its target price from $61 to quote $65, while ‘TD Cowen’ rates the stock as ‘Hold’
In other news, Boughton Soleil, Chief Legal Officer sold 2,572 shares of the company’s stock on Jun 30 ’25. The stock was sold for $129,886 at an average price of $50.50. Upon completion of the transaction, the Chief Legal Officer now directly owns 160,737 shares in the company, valued at $7.78 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 30 ’25, Officer Boughton Soleil bought 2,572 shares of the business’s stock. A total of $129,886 was incurred on buying the stock at an average price of $50.50. A total of 14.80% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $13.47 and a high of $72.98. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 1.59, and a quick ratio of 1.32. According to the stock market information, the enterprise value for the company is $10898714624, which is based on a 70.48 price-to-earnings ratio, a 2.04 price-to-earnings-growth ratio, and a beta of 2.07. The fifty day moving average price for HIMS is $51.0106 and a two-hundred day moving average price translates $34.89415 for the stock.
The latest earnings results from Hims & Hers Health Inc (NYSE: HIMS) was released for 2025-03-31. The net profit margin was 9.21% and return on equity was 36.79% for HIMS. The company reported revenue of $586.01 million for the quarter, compared to $278.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 110.67 percent.
